Asia Pacific Filgrastim Market By Drug Type (Biosimilar and Biologic), By Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Filgrastim Market
Market Report Description
The Asia Pacific Filgrastim Market would witness market growth of 9.4% CAGR during the forecast period (2021-2027).
Factor like the rising population of cancer patients, especially in developing nations like China and India, would unlock bright prospects for the Filgrastim market in the coming years. Although, the high cost attached to these biologics and strict regulatory compliance for the approval of biosimilars in developed nations would hamper the growth of the filgrastim market in the forecast years.
There are several biosimilars research going on across the world, which would accelerate the growth of the market. In addition, the availability of strong pipeline drugs is also estimated to support the growth of the filgrastim market over the forecast period.
One of the major factors augmenting the demand for filgrastim in this region is the increasing cases of cancer in developing nations like India and China. Governments across this region are taking many initiatives to aware people of the early treatment, which is estimated to propel the growth of the regional filgrastim market in the forecast period. However, many people with a low-income level cannot afford treatment for various chronic diseases, especially cancer. This would restrict the demand for filgrastim in the regional market.
Furthermore, as the healthcare system of this region is becoming stronger and governments are introducing better and cheaper healthcare facilities for the people, the demand for filgrastim would increase across this region. Although, the side effects of using filgrastim and the availability of various better alternatives would hinder the growth of the regional filgrastim market during the forecast period.
The China market dominated the Asia Pacific Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $60.3 million by 2027. The Japan market is experiencing a CAGR of 10.4% during (2021 - 2027). Additionally, The India market would witness a CAGR of 10.4% during (2021 - 2027).
Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Filgrastim Market is Projected to reach USD 953.4 million by 2027, at a CAGR of 8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Biosimilar and
- Chemotherapy induced Neutropenia
- Chronic Neutropenia and
- Other Indications
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and
- Online Pharmacies
- South Korea
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Cadila Healthcare Ltd. (Zydus Cadila)
- Apotex, Inc.
- Toksöz Group
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free